Croscarmellose Sodium
CAS 74811-65-7 · Cross-linked NaCMC · Super-disintegrant
The gold-standard super-disintegrant for immediate-release tablets and capsules. Chelora supplies pharmacopoeia-grade croscarmellose sodium — IP, BP and USP-NF — with certificate of analysis and complete documentation on every batch.
- IP / BP / USP-NF grades
- Non-DG transport
- Samples to bulk

CAS number
74811-65-7
pH (1 % disp.)
5.0 – 7.0
Pharmacopoeia
IP · BP · USP-NF
Transport
Non-DG
Product overview
Rapid swelling for rapid release
Croscarmellose sodium is a cross-linked polymer of carboxymethylcellulose sodium, engineered to swell rapidly on contact with water while remaining insoluble. This controlled insolubility is the key to its function as a super-disintegrant: the polymer absorbs water, swells to many times its dry volume and generates the internal pressure that breaks the tablet matrix apart within seconds.
Manufactured by cross-linking sodium carboxymethylcellulose with subsequent acid washing and drying, the resulting fibrous white powder retains a high degree of substitution (0.60–0.85) that drives the swelling mechanism. Unlike sodium starch glycolate, croscarmellose sodium does not form a viscous gel layer at typical use levels, which avoids any retardation of drug release.
It is effective at low concentrations — typically 2–5 % w/w — and can be incorporated both intragranularly and extragranularly for a dual disintegration effect. This versatility, combined with compatibility with most APIs, makes it one of the three super-disintegrants listed in every major pharmacopoeia (IP, BP/Ph. Eur., USP-NF).
Applications extend beyond standard tablets to orally disintegrating tablets (ODTs), capsule fills, granules and co-processed excipient systems. In each case, croscarmellose sodium ensures that the dosage form breaks down quickly enough for the API to dissolve and be absorbed within the therapeutic window.
Technical specifications
Applications & end uses
Where Croscarmellose Sodium delivers performance
Tablet super-disintegrant (primary use)
Croscarmellose sodium is one of the three major super-disintegrants used in immediate-release tablets. At 2–5 % w/w it provides rapid disintegration by swelling on contact with gastrointestinal fluid, breaking the tablet matrix into primary particles for fast dissolution.
Capsule disintegrant
Incorporated in hard gelatin and HPMC capsule fills, croscarmellose sodium promotes rapid deaggregation of the encapsulated powder plug, ensuring uniform drug release equivalent to tablet formulations.
Orally disintegrating tablets (ODTs)
ODT formulations rely on super-disintegrants to achieve disintegration within seconds in the oral cavity without water. Croscarmellose sodium’s rapid swelling and wicking action make it a preferred choice for fast-melt and lyophilised ODT platforms.
Granule disintegrant
When added intragranularly (within the granule) and/or extragranularly (outside the granule), croscarmellose sodium provides a dual disintegration mechanism — first breaking granules into fine particles, then facilitating complete deaggregation.
Co-processed with MCC for direct compression
Croscarmellose sodium is often co-processed with microcrystalline cellulose in direct-compression platforms. The combination delivers good compactibility with built-in disintegration, simplifying formulation and reducing manufacturing steps.
Nutraceutical formulations
Dietary supplement tablets and capsules use croscarmellose sodium to ensure rapid disintegration and dissolution of vitamins, minerals and herbal extracts, meeting USP <2040> dissolution requirements for nutritional products.
Available grades
Pharmacopoeia grades for every market
IP compliant
IP grade
Domestic pharma formulation, CDSCO filings
BP / Ph. Eur.
BP / Ph. Eur. grade
European and international regulatory markets
USP-NF
USP-NF grade
US-market formulations, FDA ANDA filings
Packaging options
Sealed and labelled to pharmacopoeia standard
25 kg — HDPE-lined fibre drum
Standard pharmaceutical unit with moisture barrier liner
50 kg — HDPE-lined fibre drum
Bulk contract manufacturing and large-batch production
Sample — Sealed HDPE container
Formulation development trial and QC evaluation
Documentation supplied
Complete paperwork for QC and regulatory
Certificate of Analysis (COA)
Batch-specific results for pH, sodium content, loss on drying, settling volume, degree of substitution and heavy metals.
Safety Data Sheet (SDS)
GHS-format, 16-section SDS covering handling, first aid, fire-fighting, accidental release and disposal.
Specification sheet
Limit values for each test parameter aligned to IP, BP/Ph. Eur. or USP-NF monograph.
Pharmacopoeia compliance statement
Confirmation of compliance with the relevant monograph for your regulatory filing.
Frequently asked questions
Common questions about Croscarmellose Sodium
What is the typical use level of Croscarmellose Sodium in tablets?+
How does Croscarmellose Sodium compare with other super-disintegrants?+
Should Croscarmellose Sodium be added intragranularly or extragranularly?+
Is Croscarmellose Sodium suitable for moisture-sensitive formulations?+
Is Croscarmellose Sodium classified as a hazardous material?+
What is the typical lead time for a bulk order?+
Related excipients
Other pharmaceutical excipients from Chelora
Looking for a reliable pharma chemical supplier?
Share your requirements and receive a quote with specifications and documentation.
